Votrient Tablet, Film Coated
Product Images NDC 0078-1077
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Votrient (NDC 0078-1077). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1. Kaplan-meier Curve For Progression-free Survival In Rcc By Independent Assessment For The Overall Population (treatment-naïve And Cytokine Pre-treated Populations) In Veg105192 (Votrient 03)
Figure 2. Kaplan-meier Curve For Progression-free Survival In Sts By Independent Assessment For The Overall Population In Veg110727 (Votrient 04)
Principal Display Panel Ndc 0078-1077-66 Votrient® (pazopanlb) Tablets 200 mg 120 Tablets Rx Only Each Tablet Contains 216.7 mg Of Pazopanib Hydrochloride, Equivalent To 200 mg Of Pazopanib Free Base. Dispense With Medication Guide Attached Or Provided Separately. Novartis (Votrient 01)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.